HC Wainwright Issues Positive Estimate for Talphera Earnings

Key Points

• HC Wainwright raised Talphera’s Q3 2026 EPS forecast to a loss of $0.06 per share from $0.07 and maintained a “Buy” rating with a $3.00 price target.
• Talphera reported quarterly EPS of -$0.06, matching consensus estimates. HC Wainwright projects losses of $0.23 per share for FY2026, $0.27 for FY2027 and $0.17 for FY2028.
• Analyst sentiment is mixed, with two Buy, one Hold and one Sell rating, resulting in an overall “Hold” consensus and a $3.00 average price target; the stock recently opened at $1.23.

Talphera, Inc. (NASDAQ:TLPH - Free Report) - HC Wainwright raised their Q3 2026 EPS estimates for Talphera in a report released on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.06) per share for the quarter, up from their previous forecast of ($0.07). HC Wainwright currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for Talphera's current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Talphera's Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.17) EPS.

Talphera (NASDAQ:TLPH - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06).

Several other brokerages also recently issued reports on TLPH. Wall Street Zen upgraded Talphera to a "hold" rating in a report on Saturday, August 8th. Westpark Capital started coverage on shares of Talphera in a report on Thursday, April 30th. They set a "buy" rating and a $3.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Talphera in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of Talphera to a "hold" rating in a report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Talphera currently has an average rating of "Hold" and a consensus price target of $3.00.

Talphera Price Performance

Shares of Talphera stock opened at $1.23 on Monday. Talphera has a 52 week low of $0.40 and a 52 week high of $1.57. The business has a 50 day moving average price of $1.19 and a 200-day moving average price of $0.96. The company has a market cap of $63.84 million, a PE ratio of -4.56 and a beta of 0.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. purchased a new stake in shares of Talphera during the 4th quarter valued at $658,000. Diadema Partners LP bought a new position in Talphera during the fourth quarter valued at about $156,000. Persistent Asset Partners Ltd purchased a new stake in Talphera during the fourth quarter worth about $42,000. Mariner LLC increased its holdings in Talphera by 132.0% during the fourth quarter. Mariner LLC now owns 58,000 shares of the company's stock worth $66,000 after buying an additional 33,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Talphera by 412.6% in the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company's stock worth $293,000 after purchasing an additional 207,166 shares during the period. Hedge funds and other institutional investors own 37.67% of the company's stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source